Kidney Failure Clinical Trial
Official title:
Does Incremental Initiation of Haemodialysis Preserve Native Kidney Function? A Multicentre Feasibility Randomised Controlled Trial
Patients who start haemodialysis usually retain some natural kidney function for months or
years after starting dialysis. Even a small amount of this natural kidney function can be
helpful in reducing the need for dietary and fluid restriction. There is also good evidence
that retaining a small amount of natural kidney function may provide a survival benefit for
patients on dialysis.
Most patients who commence haemodialysis start three times per week for 3.5-4 hours per
session, irrespective of the amount of natural kidney function they may have. An alternative
approach used in some kidney units is to take account of the natural kidney function in
prescribing the amount of dialysis. This may allow patients to start treatment needing to
spend less time on dialysis or even to start just twice weekly. The amount of dialysis can be
adjusted over time as natural kidney function declines. This is called "incremental
haemodialysis". Both of these approaches are considered to be standard care although it is
not known which approach is more beneficial to patients.
There are some suggestions that the frequency of dialysis may influence the rate of decline
of natural kidney function but this need to be tested in a large randomised study. To inform
the design of such a study, a smaller scale feasibility study is required.
We intend to randomise fifty new starters on haemodialysis with adequate natural kidney
function into two groups - a group who will have dialysis prescribed in the standard fashion
- three times weekly for 3.5-4 hours per session or a group who will have an incremental
start beginning with twice weekly treatment. We will investigate how many patients have
sufficient natural kidney function to be eligible, whether patients are willing to
participate and continue in the study, compare the rate of loss of kidney function between
groups, and ascertain whether this individualised dialysis approach is less intrusive to
patients. The results will be used to design a larger definitive study.
This study is feasibility randomised controlled trial.
50 patients who have newly started on haemodialysis will be recruited into the study from 4
UK centres.
Eligible patients will be approached prior to initiation of dialysis or after starting
dialysis. The details of the study will be explained to them and a Patient Information sheet
will be provided. Interested participants will be invited to the study and a written consent
will be obtained.
The participants will be randomly allocated to 2 groups.
1. Thrice weekly dialysis (control arm)
2. Incremental dialysis - Twice weekly dialysis to start with and slowly increasing the
duration and frequency of dialysis to thrice weekly depending on their native kidney
function.
All participants will be monitored at least once monthly by performing dialysis related blood
tests, urine tests, clinical evaluation, medications, weight, dialysis adequacy, adverse
events.
Questionnaire involving quality of life, mood, illness intrusiveness, functional status,
cognitive function will also be performed.
Participants will be recruited in the first year and all participants will be followed up for
12 months. All participants may withdraw at any time without any change in their dialysis
care.
To ensure independence, the University of Hertfordshire will perform randomisation, and
assist with data monitoring and data analysis.
A 6 month rate of loss of native kidney function between the 2 groups will be analysed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02546037 -
Clotting With Different Dialyzer Membranes
|
||
Recruiting |
NCT02545920 -
To Assess Ear Blood Flow During Dialysis
|
||
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A | |
Completed |
NCT01158742 -
Live Kidney Donor Study -Renal Function Study
|
N/A | |
Completed |
NCT00986947 -
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
|
Phase 2 | |
Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
Withdrawn |
NCT00807274 -
Renal Function in Adults With Congenital Heart Disease.
|
N/A | |
Completed |
NCT00369382 -
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
|
Phase 4 | |
Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05324878 -
Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
|
||
Completed |
NCT05272800 -
BIS-guided Fluid Management in HD Patients
|
N/A | |
Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Completed |
NCT03723668 -
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
|
||
Recruiting |
NCT04277377 -
Nanoparticle for DSA Removal
|
||
Terminated |
NCT00450333 -
Dynepo Infrequent Dosing Study
|
Phase 3 | |
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT04714853 -
Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins
|